Quanterix Corporation QTRX

The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher

Quanterix (QTRX) is back in focus after its 10 August second quarter report, which paired higher revenue with a wider net loss, a lower full year 2026 revenue outlook, and a new Chief Commercial Officer. See our latest analysis for Quanterix. Quanterix’s share price has been under pressure for some time, with the year to date share price return down 59.18% and the 1 year total shareholder return down 44.85%. The stock briefly rebounded with an 8.47% 1 day share price gain after the 10 August...

Quanterix Corp (QTRX) lowers full-year 2026 revenue guidance to $142-$148 million as it navigates broad-based market headwinds and pushes cash flow break-even to 2027.

Quanterix reported 34% second-quarter revenue growth and lower adjusted cash usage, but weaker-than-expected commercial performance prompted a substantial guidance reduction and pushed expected cash-flow break-even into 2027. Key Investor TakeawaysQuanterix (NASDAQ:QTRX) reported Q2 2026 revenue of $32.

BILLERICA, Mass., August 10, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company’s commercial operations.

BILLERICA, Mass., August 10, 2026--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026.

BILLERICA, Mass., August 06, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026.

BILLERICA, Mass., August 04, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results.

Dublin, July 21, 2026 (GLOBE NEWSWIRE) -- The "Biomarker Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering.This report provides a comprehensive and structured analysis of 590+ biomarker collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.The definitive benchmark for biomarker dealmaking Biomarker partnering is driven by data, discovery, and precisi

BILLERICA, Mass., July 16, 2026--Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass., July 14, 2026--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment.

Quanterix is back in focus after analysts trimmed their fair value price target from US$5.33 to US$4.33, tightening the implied upside range for the stock. Research firms describe this as a recalibration tied to refreshed assumptions rather than a wholesale change in the core outlook on Quanterix. Read on to see what is driving the revised targets, how bullish and cautious voices differ, and what it could mean for investors following the evolving narrative from here. Analyst Price Targets...